

1 **Title**

2 **Multiomic deep delve of synthesis and secretion processes in a model peptidergic system**

3 *Soledad Báñez-López^{1*}, André S. Mecawi^{2*}, Natasha Bryan¹, Benjamin T. Gillard¹, Audrys G. Pauza¹, David*
4 *Murphy^{1†} and Michael P. Greenwood^{1†}*

5 **Authors/affiliations**

6 ¹Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences,
7 University of Bristol, Dorothy Hodgkin Building, Bristol, United Kingdom.

8 ²Laboratory of Neuroendocrinology, Department of Biophysics, Paulista School of Medicine, Federal
9 University of São Paulo, São Paulo, Brazil.

10 **Author list footnotes**

11 *Equal first authors

12 †Equal senior authors

13 Correspondence: mike.greenwood@bristol.ac.uk, d.murphy@bristol.ac.uk

14 **Abstract**

15 The cell bodies of hypothalamic magnocellular neurones are densely packed in the hypothalamic
16 supraoptic nucleus (SON) whereas their axons project to the anatomically discrete posterior pituitary
17 gland. We have taken advantage of this unique anatomical structure to establish proteome and
18 phosphoproteome dynamics in neuronal cell bodies and axonal terminals in response to physiological
19 stimulation. We have found that proteome and phosphoproteome responses are very different between
20 somatic and axonal neuronal compartments, indicating the need of each cell domain to differentially
21 adapt. In particular, changes in the phosphoproteome in the cell body are involved in the reorganisation
22 of the cytoskeleton and in axonal terminals the regulation of synaptic and secretory processes. We have
23 identified that prohormone precursors including vasopressin and oxytocin are phosphorylated in axonal
24 terminals and become hyperphosphorylated following stimulation. By multi-omic integration of
25 transcriptome and proteomic data we identify changes to proteins present in afferent inputs to this
26 nucleus.

27 **Introduction**

28 Determining the integrative transcriptome, proteome and phosphoproteome of a given cell type at any
29 given time is rather challenging, but this is particularly complicated in neurones. It is recognised that
30 neurones have distinct protein populations in their cell bodies and axons (Costa and Willis, 2018; Sahoo
31 et al., 2018). Since proteins and their phosphorylation events control cellular function, it is imperative to
32 separately determine the proteomes and phosphoproteomes of cell bodies and axonal terminals to better
33 understand cellular processes in health and disease. The complex projection patterns of neurones makes
34 this challenging for most brain nuclei.

35 Because of its unique anatomical structure, there is one neuronal system that is ideally suited to overcome
36 many of these inherent challenges. The hypothalamo-neurohypophysial system (HNS) is a key
37 neuroendocrine interface that connects the hormonal, neuronal, and vascular systems in all vertebrate
38 species (Burbach et al., 2001; Mecawi et al., 2015). Hormones, such as antidiuretic hormone arginine
39 vasopressin (AVP) and oxytocin (OXT), are made by densely packed populations of magnocellular
40 neurones (MCN) predominantly located in the hypothalamic supraoptic (SON) and also the
41 paraventricular nucleus (PVN). MCNs have one long axon that terminates in the posterior lobe of the
42 pituitary gland (PP) and collaterals that project into other regions of the brain (Zhang et al., 2021). The PP
43 is composed of pituicytes, approximately 30% by volume, and up to 36 million nerve terminals and
44 swellings based on estimates of 18000 MCNs each with one long axon giving rise to an estimated 2000
45 nerve terminals and swellings (Leng and Ludwig, 2008). Each axon terminal contains ~260 dense core
46 vesicles packed with peptide hormones, including AVP and OXT, that are destined for release into the
47 blood (Nordmann, 1977).

48 When the HNS is osmotically stimulated, such as evoked by water deprivation (WD), there is an increase
49 in hormone release from the PP into the blood as the nerve endings are depolarised (Brownstein et al.,
50 1980). Chronic osmotic stimulation of MCNs results in a striking functional remodelling of the HNS through
51 several activity-dependent changes in the morphology, electrical properties and biosynthetic and
52 secretory activity of the SON (Hatton, 1997; Sharman et al., 2004; Theodosis et al., 1998), which contribute
53 to the facilitation of hormone synthesis, vesicle transportation, and secretion. Whilst this plasticity has
54 been explored extensively at the transcriptome level (Dutra et al., 2021; Greenwood et al., 2015b;
55 Hindmarch et al., 2006; Johnson et al., 2015; Pauža et al., 2021; Qiu et al., 2011), dynamic changes in the
56 proteome and phosphoproteome have not thus far been addressed.

57 In this work we explore the proteomes and phosphoproteomes of the SON and the neurointermediate
58 lobe (NIL) of the pituitary gland under basal and WD conditions. By integrating transcriptome catalogues,
59 we comprehensively describe dynamic biosynthetic and secretory strategies that fuel the outputs of
60 MCNs.

61

62 **Results**

63 *Quantitative proteome and phosphoproteome of the rat SON*

64 To stimulate MCNs, animals were WD for 48 hours. Stimulated animals were compared to euhydrated
65 controls. The SON (containing MCN cell bodies and dendrites) was punched from the hypothalamus and
66 the NIL (containing axonal terminals in the PP and the intermediate lobe) was dissected from the anterior
67 lobe of the pituitary. Proteins were extracted and processed for Nano-LC Mass Spectrometry (LC-MS/MS,
68 **Figure 1A**). A catalogue of proteins detected in the SON and NIL and differentially produced proteins and
69 phosphosites between control and WD rats is presented in the supporting information (Tables S1 and S2).

70 Proteome analysis of the SON identified 7668 proteins (Table S1). Principal component analysis (PCA) of
71 proteome and phosphoproteome data did not reveal a separation pattern between control and WD
72 groups (**Figure 1B**). Of the 7668 proteins detected in the SON, the data indicated 325 differentially
73 abundant proteins in WD SON, with 247 being increased and 78 decreased in content (**Figure 1C**). We
74 asked about the phosphorylation status of identified proteins. We found that 229 proteins underwent
75 changes in phosphorylation in response to WD (p-value < 0.05), which included 252 hyperphosphorylation
76 and 36 hypophosphorylation events (**Figure 1D**). Only 23 proteins that changed in overall content also had
77 phosphorylation modifications in response to WD (**Figure 1E**).

78 The phosphoproteome data was validated using commercially available phospho-antibodies against
79 significantly altered phosphosites in the control and WD SON. We investigated phosphosites for 40S
80 ribosomal protein S6 (S6; S244-p) that showed a Log₂ Fold Change (Log₂FC) of 1.13 (p-value = 5.62E-03),
81 Nitric oxide synthase (NOS1, S1412-p) with a Log₂FC of 0.36 (p-value = 2.89E-02), STATHMIN1 (STMN1,
82 S25-p) with a Log₂FC of 0.55 (p-value = 1.55E-02) and JUND (S255-p) with a Log₂FC of 0.51 (p-value =
83 3.07E-02) (**Figure 1F**). In addition, we immunolabelled S6, NOS1 and STMN1 proteins.
84 Immunohistochemical studies supported increased phosphorylation of S6 S244-p in MCNs (**Figure 1G, G'**)
85 with no change to S6 protein content (**Figure 1H, H'**). The phosphorylation of the S1412-p residue of NOS1

86 (Figure 1I, I') appeared to increase in a population of MCNs that produce NOS1 (Figure 1J, J').
87 Immunostaining against S25-p STMN1, detected the presence of this phospho residue in the SON and
88 revealed increased staining in MCNs in response to WD (Figure 1K, K'). No differences were observed in
89 immunostaining of the STMN1 protein (Figure 1L, L'). Immunostaining of S255-p JUND revealed the
90 presence of this phospho residue in the SON and confirmed an increase in phosphorylation in MCNs in
91 WD (Figure 1M, M'). We have previously reported increased JUND protein content by western blot and
92 immunohistochemistry in the WD SON (Yao et al., 2012). All these findings agreed with the LC-MS/MS
93 output.

94 *Quantitative proteome and phosphoproteome of the rat NIL*

95 Proteome analysis identified 9303 proteins in the NIL (Table S2). PCA using all proteins revealed distinct
96 separation between the total proteomes of control and WD samples with PC1 accounting for 26% of total
97 variance between samples, which was attributable to WD (Figure 2A). PCA also displayed a distinctive
98 separation between the phosphoproteomes of control and WD samples with PC1 explaining 19.8% of the
99 total variance between samples, that was attributable to the experimental condition (Figure 2A). Out of
100 9303 total proteins, 870 changed their protein content as a consequence of WD (p-value < 0.05) with 282
101 proteins decreasing their total content and 588 increasing their total protein content (Figure 2B). We
102 again asked about the phosphorylation status of identified proteins. We found that 760 proteins
103 underwent changes in phosphorylation (p-value < 0.05), which included 746 hyperphosphorylation and
104 755 hypophosphorylation events (Figure 2C). A total of 151 proteins with alterations to their overall
105 content also underwent changes in phosphorylation in WD (Figure 2D).

106 NIL phosphoproteome data was validated by western blot and immunohistochemistry. We used
107 commercially available phospho-antibodies against the phosphosites of Synapsin 1 (SYN1, S67-p) that
108 showed a Log2FC of 0.74 (p-value = 1.12E-06), Synapsin 2 (SYN2, S426-p) with a Log2FC of -1.49 (p-value
109 = 3.21E-09), and NOS1 (S847-p) with a Log2FC of 0.67 (p-value = 8.30E-04) (Figure 2E), as well as antibodies
110 against SYN and NOS1 proteins. Immunoblotting confirmed an increase in SYN1 S67-p, decrease in SYN2
111 S426-p, and increased NOS1 S847-p following WD (Figure 2E; S1). Immunostaining showed the location
112 of these phosphosites predominantly in the PP which was marked with AVP (Figure 2F). Higher
113 magnification images of the PP in WD confirmed an increase in SYN1 S67-p, a decrease in SYN2 S426-p,
114 and an increase in NOS1 S847-p (Figure 2G). Overall, the pattern of phosphoregulation observed in the
115 SON and NIL agreed with the LC-MS/MS output.

116 *Pathway analyses and functional classification of the proteomes and phosphoproteomes of SON and NIL*

117 To gain functional insights into the responses of the MCN compartments localised in the SON and NIL to
118 WD, we performed pathway analysis of the differential produced proteins between control and WD
119 samples by interrogating GO and KEGG databases. We show enriched terms (restricted to up to 15 terms)
120 retrieved for each category ranked according to P_{Adj} value (**Figure 3**). In addition, we plotted the topmost
121 significant associated differentially produced proteins coloured based on Log2FC and sized according to
122 total normalised protein following WD. In the SON, all the terms retrieved for the GO:Cellular
123 Compartment Process (GO:CC) and GO:Biological Process (GO:BP) categories highlighted terms associated
124 with the endomembrane system including the endoplasmic reticulum (ER), the Golgi apparatus, as well as
125 Golgi-associated vesicles and COPI-coated vesicles (**Figure 3A** and **Table S3**). No enriched terms were
126 identified in the GO:Molecular Function Process (GO:MF) category. Over-representation analysis by KEGG
127 identified “Protein processing in endoplasmic reticulum” as an enriched pathway (**Figure 3A** and **Table**
128 **S3**). Strikingly, most of the top-regulated proteins increased their content in response to WD. Amongst
129 the most abundant proteins following WD were a series of chaperones known to regulate protein folding
130 and stress in the ER including the Heat Shock Protein Family A (Hsp70) Member 5 (HSPA5) also known as
131 Endoplasmic reticulum chaperone BiP, the Hypoxia up-regulated protein 1 (HYOU1), Protein disulfide-
132 isomerase (P4HB) and calreticulin (CALR) (Ni and Lee, 2007).

133 In the NIL, terms highlighted in the GO:CC category included “synapse”, “presynapse” and “secretory
134 vesicle”, amongst others (**Figure 3B** and **Table S3**). In the GO:MF hierarchy and the KEGG pathway, all
135 terms were related to endopeptidase activity, probably triggered by the changes in hormone content,
136 shown here by AVP, in response to WD (**Figure 3B** and **Table S3**). The GO:BP included several terms related
137 to wounding and coagulation, but more pertinent to the present study were the several terms related to
138 synaptic signalling, regulation of transport or regulation of body fluid levels (**Figure 3B** and **Table S3**). KEGG
139 analysis identified the enriched pathway “Complement and coagulation cascades” (**Figure 3B** and **Table**
140 **S3**). The coagulation-related terms identified in the GO:BP and KEGG analysis, such as coagulation factor
141 V (F5), Platelet-derived growth factor subunit A (PDGFA) or Plasma protease C1 inhibitor (SERPING1),
142 could be related to dehydration-mediated blood coagulation activation (Shi et al., 2019) or to the increase
143 in perivascular protrusions that have been described in the PP following chronic stimulation (Miyata,
144 2017). Some of the proteins with biggest Log2FC included those involved in “regulation of fluid levels”,
145 such as the peptides AVP and OXT or the enzyme peptidylglycine alpha-amidating monooxygenase (PAM),
146 that mediates C-amidation of endogenous peptides including AVP and OXT (Yin et al., 2011). Other

147 proteins with large Log2FC were serine-protein kinase ATM (ATM) involved in vesicle transport
148 (Pizzamiglio et al., 2020) or receptor-type tyrosine-protein phosphatase N2 (PTPRN2), also involved in
149 vesicle-mediated secretory processes (Wasmeier et al., 2005). Altogether, these data suggests that
150 changes in the proteome in response to WD in the SON are associated with protein synthesis, whilst in
151 the NIL they are related to synaptic signalling and transport.

152 To further investigate differentially produced proteins in separate compartments of the HNS, we mined
153 the IUPHAR (Harding et al., 2022) and a transcription factor database (Lambert et al., 2018) to report
154 physiological and pharmacological classifications or identity as transcription factors. In the SON (**Figure**
155 **3C**), 6 differentially synthesised proteins were classified as peptides, 5 increasing and 1 decreasing in
156 protein content. Notably, this included increased AVP and Proenkephalin-B (PDYN) which are known to
157 be increased in MCNs of the WD SON (Pauža *et al.*, 2021). The largest category was enzymes which was
158 much more evenly weighted with proteins increasing and decreasing in content. In the NIL (**Figure 3D**), a
159 series of peptides increased their content while others, such as OXT, AVP, and PDYN decreased, illustrating
160 the known role for the PP in peptide secretion (Brown, 2016). Several enzymes also changed their content
161 in the NIL in response to WD, but none of these coincided with those in the SON, suggesting different
162 adaptation to WD between these two structures.

163 We next performed pathway analysis using GO and KEGG databases to explore the phosphoproteome
164 changes as a result of WD in the SON and NIL. We ranked according to P_{Adj} value up to 15 of the enriched
165 terms identified in each category and we plotted the proteins with most significant phosphorylation
166 changes in a phosphosite. In addition, we indicate the total number of phosphorylation events in that
167 protein following WD (**Figure 4**). In the SON, the only term retrieved in the GO:CC category was “cell
168 junction” whilst both the GO:MF and the GO:BP hierarchies highlighted terms related to microtubule and
169 cytoskeleton binding and organisation (**Figure 4A** and **Table S3**). We identified phosphorylation changes
170 in several microtubule-associated proteins (MAPs), organisers of the microtubule cytoskeleton
171 (Bodakuntla et al., 2019), including MAP2, MAP1A and MAPT. We also found phosphorylation events in
172 STMN1, known to control microtubule dynamics (Benarroch, 2021; Rubin and Atweh, 2004) and other
173 microtubule-organising proteins such as Calmodulin-regulated spectrin-associated protein 2 (CAMSAP2)
174 (Yau et al., 2014) and Microtubule crosslinking factor 1 (MTCL1). No significantly enriched terms were
175 identified in the KEGG pathways.

176 In the NIL the GO:CC highlighted several terms including “synapse”, “presynapse” and “cytoskeleton”. The
177 GO:MF category retrieved several terms related to protein binding and the GO:BP hierarchy highlighted

178 terms related to cellular organisation and localisation in addition to other terms related to secretion and
179 synaptic signalling and transmission (**Figure 4B** and **Table S3**). As such, phosphorylated proteins were
180 mainly involved in cytoskeleton organisation and localisation of cellular components including MAP1B,
181 MAP1A, Ankyrin-2 (ANK2) and Band 4.1-like protein 1 (EPB41L1) or in secretion and synaptic transmission
182 including vesicle-associated membrane protein 2 (VAMP2), SYN1 and Syntaxin-binding protein 5 (STXBP5).
183 No enriched terms were identified in the KEGG pathways. We thus establish that changes in
184 phosphorylation in response to WD in the SON are involved in cytoskeleton organisation whereas in the
185 NIL they also regulate synaptic and secretory processes.

186 We then globally quantified changes in phosphorylation in order to obtain single values for changes in the
187 overall phosphorylation status of individual proteins. This analysis measured the overall phosphorylation
188 state change (Δ Ps) of each protein as described by Wang et al. (2018). In the SON, the Δ Ps showed that
189 47 proteins were significantly hyperphosphorylated (Δ Ps > 0.34) whilst 7 were hypophosphorylated (Δ Ps
190 < -0.34) (**Figure 4C**). The top 3 Δ Ps hyperphosphorylated proteins were MAP2, S6 and Cytoplasmic
191 activation/proliferation-associated protein 2 (CAPRIN2) and the hypophosphorylated proteins were G-
192 protein coupled receptor-associated sorting protein 1 (GPRASP1), Disintegrin and metalloproteinase
193 domain-containing protein 22 (ADAM22) and Glycogen synthase (GYS1). In the NIL, the Δ Ps analysis
194 revealed 157 significant hyperphosphorylated (Δ Ps > 0.4) proteins and 117 hypophosphorylated proteins
195 (Δ Ps < 0.4) (**Figure 4D**). The top 3 Δ Ps hyperphosphorylated proteins were NOS1, STMN1 and ANK2 while
196 the hypophosphorylated ones included Secretogranin-1 (CHGB), SYN2 and MAP kinase-activating death
197 domain protein (MADD).

198 We then plotted the proteins with significant changes in Δ Ps in response to WD and classified them
199 according to their physiological and pharmacological classifications or their identity as transcription
200 factors in the SON (**Figure 4E**) and the NIL (**Figure 4F**). The Δ Ps changed in only 1 peptide in the SON whilst
201 several peptides underwent changes in phosphorylation in the NIL, including AVP, OXT and PDYN, all of
202 which decreased their total protein content in the NIL following WD (**Figure 4D**). This finding strongly
203 suggests that changes in peptide phosphorylation in the NIL might be related to peptide secretion. Several
204 enzymes had changed Δ Ps in the SON and NIL including, of note, NOS1 which was hyperphosphorylated
205 in both structures (**Figure 4C, D** and **S2**). Additionally, various transporters had significant changes in their
206 Δ Ps in the NIL, with only 1 in the SON.

207 *Phosphorylation adaptations in the SON and NIL in response to WD*

208 Pathway analysis of the changes in the phosphoproteome following WD were indicative of important
209 differential adaptations in the SON and the NIL. Phosphorylation modifications in the SON seemed to
210 mediate cytoskeleton remodelling whilst in the NIL they were related to synaptic events. To further
211 explore post-translational events elicited by WD, we mapped the phosphorylation sites identified by LC-
212 MS/MS to proteins involved in selected ontology terms.

213 In the SON, we explored the only GO:BP term retrieved: “microtubule cytoskeleton organisation” (**Figure**
214 **4A**). We mapped all phosphosites detected in this structure by LC-MS/MS highlighting those that
215 underwent hyper or hypophosphorylation events in selected proteins from this GO category (**Figure 5**).
216 These included Centrosomal protein of 131 kDa (CEP131), Mapb1, Cytoplasmic Linker Associated Protein
217 2 (CLASP2), Multiple PDZ domain protein (MPDZ), Pleckstrin homology-like domain family B member 1
218 (PHLDB1), CAMSAP2, MAP2, MTCL1, STMN1, MAP1A, MAP7 domain-containing protein 1 (MAP7D1) and
219 Microtubule Affinity Regulating Kinase 4 (MARK4), among others. All these proteins were
220 hyperphosphorylated, with the exception of MAP7D1 that was hypophosphorylated and MAP1B that was
221 both hyper and hypophosphorylated at different residues. To further explore the phosphorylation events
222 in synapse-related categories in the NIL, we used SynGO analysis (Koopmans et al., 2019) to detail
223 synapse-specific changes. For the cellular compartment ontology, the most enriched terms revealed were
224 at the level of the presynapse (**Figure 6A**). Biological Process ontology terms highlighted terms such as
225 “process in the presynapse”, “synaptic vesicle cycle” and “presynaptic dense core vesicle (DCV)
226 exocytosis” (**Figure 6B, Table S4**). We mapped all phosphosites detected for some of the proteins involved
227 in the “synaptic vesicle cycle” category, which can be further classified into terms “regulation of synaptic
228 vesicle cycle” composed of the proteins Bassoon (BSN), SYN1 and Rho GDP Dissociation Inhibitor Alpha
229 (ARHGDI1A), “synaptic vesicle clustering” comprising Piccolo (PCLO), Synapsin 3 (SYN3), SYN2, Abelson
230 interactor 1 (ABI1) and BSN and “synaptic vesicle exocytosis” which included the proteins Synaptosomal-
231 Associated Protein, 25kDa (SNAP25), VAMP2, unc-13 homolog A (UNC13A), Syntaxin 1B (STX1B) and
232 Synaptotagmin 2 (SYT2), amongst others (**Figure 6C**). For the term “presynaptic dense core vesicle
233 exocytosis” we mapped the phosphosites for some of the proteins in this category which included
234 Calcium-dependent secretion activator 1 (CADPS), Regulating synaptic membrane exocytosis protein 1
235 (RIMS1), SNAP25, Dynamin-1 (DNM1), Syntaxin-binding protein 1 (STXBP1), STXBP5 and Ras-related
236 protein Rab-3A (RAB3A) (**Figure 6C**). By mapping the phosphosites to these proteins as well as the
237 hyperphosphorylation and hypophosphorylation sites, we highlight a series of phosphorylation events
238 potentially involved in cytoskeleton organisation, the synaptic vesicle cycle and DCV exocytosis.

239 *Multiomic integration of stimulated SON and NIL*

240 Next, we performed an integrative analysis of the differential transcriptomes, proteomes and
241 phosphoproteomes of the SON and NIL by Spearman correlation analysis. This was done by comparing
242 the proteome and phosphoproteome data with transcriptomic analysis of the 72-hour WD Wistar Han
243 rats (Pauža et al., 2021). Spearman correlation analysis between differentially expressed genes and
244 proteins in the SON in response to WD revealed a positive correlation ($r = 0.55$, p -value < 0.0001 ; **Figure**
245 **7A**) indicating that, in response to a stimulus such as WD, increased steady-state transcript abundance in
246 general leads to increased translation in the SON. There was no such correlation between differentially
247 expressed genes in the SON and differentially produced proteins in the NIL in response to WD (Spearman
248 $r = -0.099$, p -value = 0.368; **Figure 7B**). However, there were a number of proteins with increased gene
249 expression in the SON and decreased protein content in the NIL (such as AVP, PDYN, PCSK1 or PCSK5).
250 This illustrates how the SON synthesises proteins which are then transported for release from the PP in
251 response to stimulation. Moreover, the changes in total proteome between the SON and NIL in response
252 to WD did not correlate (Spearman $r = -0.209$, p -value = 0.285; **Figure 7C**). A similar pattern was observed
253 with the phosphoproteomes, where the Δ Ps between the SON and the NIL did not show a statistically
254 significant correlation (Spearman $r = 0.140$, p -value = 0.171; **Figure 7D**). This implies cell compartment
255 specific changes in response to WD. We next explored the relationship between changes in Δ Ps in the NIL
256 and changes in the total proteome in response to WD in the SON. Spearman correlation analysis revealed
257 a positive correlation (Spearman $r = 0.495$, p -value = 0.014; **Figure 7E**). This suggests that, following WD,
258 the SON synthesises proteins that are transported to the NIL, where they are hyperphosphorylated. In
259 addition, exploring the relationship between changes in Δ Ps in the NIL in response to WD and the changes
260 in the total proteome in response to WD in the NIL showed a negative correlation (Spearman $r = -0.518$,
261 p -value = 0.0001; **Figure 7F**) suggesting that, in response to a stimulus such as WD, hyperphosphorylated
262 proteins are secreted from the NIL into the circulation or are degraded. Among the proteins that are
263 hyperphosphorylated and secreted from the NIL were the peptides AVP, OXT, PDYN and the enzyme PAM
264 responsible for peptide C-amidation (Yin *et al.*, 2011). To further explore the possible role of
265 hyperphosphorylation in the secretion of these proteins, we mapped the identified phosphosites in the
266 SON and the NIL to the protein sequence (**Figure 7G**). Interestingly, in the SON, none of these proteins
267 underwent any changes in phosphorylation to WD, indeed they presented no phosphorylation events at
268 all. In the NIL we detected 8 phosphosites (7 of them described in the present the work from the first
269 time), 4 of which were hyperphosphorylated in response to WD. Two novel sites were found for OXT and
270 one of them was hyperphosphorylated in response to WD. For PDYN we identified 6 phosphosites, 3 of

271 which were hyperphosphorylated following stimulus. Of the 2 phosphosites identified in PAM in the NIL,
272 one was hyperphosphorylated as a consequence of neuronal activation.

273 *Basal state transcriptome vs proteome integration*

274 We then explored the relationship between the transcriptomes and the proteomes of SONs in the basal
275 condition by comparing the proteome data with transcriptomic analysis in Wistar Han rats (Pauža *et al.*,
276 2021). We compared transcripts in the RNAseq dataset with a mean number of reads > 10 with the LC-
277 MS/MS total proteome data from SON and NIL in euhydrated conditions. These comparisons revealed
278 important transcriptome and proteome dynamics in cell bodies and axonal terminals (**Figure 8A, B**). To
279 begin with, there were 6862 transcripts for which the corresponding encoding proteins were not detected
280 by LC-MS/MS. This can be attributed to the lower sensitivity and dynamic range for detection of
281 proteomics and to technical issues such as protein solubility (Dapic *et al.*, 2017). Interestingly, there were
282 6143 transcripts in the SON which encoded proteins were detected in both the SON and NIL, likely
283 representing a mix of proteins synthesised in the cell body and transported to the axonal terminals and/or
284 synthesised in different cell populations in the SON and NIL. There were 293 proteins exclusively present
285 in the NIL, without their corresponding transcripts in the SON, suggesting either local synthesis of these
286 proteins in the NIL, inputs from non-SON neurones projecting to the NIL, or contamination from blood.
287 There were 1372 transcripts in the SON which encoded proteins present in the NIL but not the SON,
288 possibly reflecting protein transport from cell bodies in SON to axonal terminals in NIL. In addition, there
289 were 852 transcripts with proteins present in the SON, but not the NIL, suggesting that these proteins are
290 synthesised in the SON, but are not transported to the PP, instead having unique biological functions in
291 cells bodies and dendrites, or that they are produced in SON cells other than MCNs.

292 Interestingly, there were 673 proteins detected in the SON without a corresponding transcript (**Figure 8A,**
293 **B**). We hypothesised these proteins may provide novel insights regarding SON neuronal circuit
294 connectivity. However, it is important to bear in mind that the discrepancy between RNA and presence of
295 protein could in some cases be due to contamination from proteins present in the blood or to differences
296 in the rat strains used in the transcriptomic and the proteomic analysis. We classified these proteins
297 according to their identity as transcription factors or their physiological or pharmacological categories and
298 included 15 peptides, 23 enzymes, 2 GPCR, 2 channels, 9 transporters and 2 transcription factors (**Figure**
299 **8C**). We identified Hypocretin neuropeptide precursor (HCRT) as a candidate peptide being transported
300 into the SON. Interestingly, the protein abundance of HCRT was increased in response to WD.
301 Immunohistochemistry identified HCRT positive afferent fibres (**Figure 8D**), possibly arising from neuronal

302 cell bodies in the lateral and posterior hypothalamus (Date et al., 1999) and was indicative of increased
303 HCRT protein content in the SON (**Figure 8D, D'**). In addition, Neuropeptide Y (NPY), Agouti related protein
304 (AGRP), and Preproglucagon (GCG) were detected at the protein but not mRNA level. The presence of
305 Glucagon-like peptide 1 (GLP1) in afferent fibres within the SON is well-known (Tauchi et al., 2008),
306 possibly arising from the nucleus tractus solitarius (Kabahizi et al., 2022). Immunostaining of NPY revealed
307 axonal terminals containing NPY peptide in the SON (**Figure 8E**) possibly projecting from other
308 hypothalamic structures (Chronwall et al., 1985; Kask et al., 2002). In agreement with LC-MS/MS, no
309 changes in NPY immunolabelling were observed in response to WD (**Figure 8E, E'**). We also detected the
310 presence of AGRP-containing axonal fibres in the SON (**Figure 8F**) and again observed no change in
311 response to WD (**Figure 8F, F'**). Thus, we have identified several signalling proteins that could potentially
312 be transported into the SON from other brain regions to mediate functional outcomes.

313 **Discussion**

314 In this work we have explored the proteomes and phosphoproteomes of different compartments of the
315 SON and NIL under basal and stimulated conditions. Through comparisons with corresponding SON
316 transcriptomes, we bring a novel perspective to transcriptome, proteome and phosphoproteome
317 dynamics in this uniquely tractable model neuronal system.

318 Whilst it is well known that proteins synthesised in SON cell bodies are transported to axonal terminals in
319 the PP, our data globally quantifies this phenomenon. When stimulated, MCNs change their steady-state
320 RNA levels and proteomes. In response to WD, proteome and phosphoproteome dynamics differ between
321 the SON and NIL, showing that each neuronal compartment adapts in a very distinctive way to facilitate
322 changes to cell secretory requirements. In the SON, this involves the synthesis of new proteins to meet
323 the demand for newly synthesised peptides (such as AVP and OXT) and associated secretory machinery.
324 The protein phosphorylations in the SON in WD seem to mediate separate functions related to
325 cytoskeleton organisation. In particular, MAP1B S1256 phosphorylation site has already been shown to
326 contribute to the regulation of microtubule dynamics (Trivedi et al., 2005). Also, phosphorylation of the
327 STMN1 phosphosites identified in this work have been shown to promote microtubule stability (Honnappa
328 et al., 2006) and S25-p and S38-p have been found to be phosphorylated in response to hyperosmotic
329 stress (Ng et al., 2010). It has been demonstrated that MNCs have a distinctive cytoskeleton composed of
330 a layer of actin filaments beneath the plasma membrane and a unique network of cytoplasmic actin
331 filaments and microtubule interweaved scaffold (Barad et al., 2020; Prager-Khoutorsky et al., 2014). The
332 cytoskeleton of MCNs undergoes reorganisation in response to hyperosmotic stimuli, which is believed to

333 underlie the intrinsic osmosensitivity of MNCs (Barad *et al.*, 2020; Hicks *et al.*, 2020; Prager-Khoutorsky *et al.*, 2014). Our data suggests that phosphorylation events in response to WD in the SON may contribute
334 to changes in the cytoskeletal organisation in MNCs. Furthermore, we have also mapped the phosphosites
335 that change in response to WD in proteins involved in cytoskeleton remodelling, such as MAP and other
336 microtubule-organising proteins, providing a global overview of the phosphorylation events mediating
337 cytoskeleton reorganisation.
338

339 In the NIL, pathway analysis for changes in the proteome and phosphoproteome in WD informed of
340 adaptations to the synaptic vesicle cycle instrumental for secretion. By mapping phosphosites and
341 responses to stimuli, we provide a global overview of the phosphorylation events involved in the synaptic
342 vesicle cycle and secretion. We report a catalogue of the phosphorylation events that take place in known
343 proteins of the synaptic vesicle cycle, synaptic vesicle clustering, and synaptic exocytosis. These include
344 critical proteins of the synaptic vesicle cycle such as PCLO, BSN and proteins from the VAMP, SNAP,
345 syntaxin, synaptotagmin and synapsin families. Although most of the phosphorylation events that we
346 describe have no currently known functions, some have already been explored. BSN phosphorylation at
347 S2845 has been shown to modulate its anchoring to the presynaptic cytomatrix as part of presynaptic
348 remodelling during synaptic plasticity (Schroder *et al.*, 2013). Phosphorylation of SYN1 at S62/67 causes
349 the dissociation of synaptic vesicles from the actin cytoskeleton resulting on their mobilisation from the
350 reserve pool to the release-ready pool (Chi *et al.*, 2003). Phosphorylation of SNAP25 at T138 inhibits
351 assembly of the SNARE complex and exocytosis (Gao *et al.*, 2016), but increases the size of releasable
352 vesicle pools (Nagy *et al.*, 2004). S14-phosphorylated STX1B has been shown to interact with SNAP25 in
353 specific domains of the axonal plasma membrane with no pools of synaptic vesicles suggesting that these
354 could be fusion sites for a novel class of vesicles beyond traditional active zones. These findings further
355 support the role of these phosphorylation changes in the synaptic vesicle cycle in the HNS. We also provide
356 a catalogue of the phosphorylation events taking place for proteins involved in “presynaptic DCV
357 exocytosis” which include the proteins CADPS, required for Ca²⁺-activated DCV exocytosis (Berwin *et al.*,
358 1998), RIMS1, DNM1, RAB3A and the syntaxin binding proteins STXBP1 and STXBP5. It has been described
359 that DNM1 is constitutively phosphorylated at S778. This residue is dephosphorylated following neuronal
360 stimulus to facilitate synaptic vesicle endocytosis, which is necessary to maintain a pool of synaptic
361 vesicles within nerve terminals after exocytosis, following which it is rephosphorylated to allow for the
362 next round of synaptic vesicle endocytosis (Tan *et al.*, 2003).

363 The negative correlation between the Δ Ps and the proteome in the NIL as a result of WD suggests that
364 hyperphosphorylation of proteins maybe a key component for neuropeptide processing and/or secretion
365 from nerve terminals. In particular, in the AVP and PDYN precursor proteins we have identified
366 phosphorylation events next to the cleavage sites suggesting that changes in phosphorylation might
367 regulate processing, as it has already been observed for gastrin (Bishop et al., 1998).

368 The protein NOS1 had high Δ P values both in the SON and the NIL. Interestingly, by mapping the
369 phosphorylation sites and their changes to WD, both in the SON and NIL, we show cell compartment
370 specific phosphorylation patterns (**Figure S2**). We detected hyperphosphorylation events in the flavin
371 mononucleotide (FMN)-binding domain in the SON and NIL as a result of WD, where increased
372 phosphorylation at S847 in the NIL, but not the SON, has been shown to reduce NOS1 activity by inhibiting
373 the binding of Ca^{2+} to the calmodulin domain (Hayashi et al., 1999; Komeima et al., 2000). In addition,
374 NOS1 phosphorylation at S1412 in the NADPH-binding domain (hyperphosphorylated in SON, but not NIL)
375 has been shown to increase the activity of NOS1 (Chen et al., 2021; Khan et al., 2015). It has been
376 suggested that hyperosmotic stimulation induces NO production in MCNs in the SON (da Silva et al., 2013;
377 Reis et al., 2015) reducing AVP and OXT secretion as a feedback compensatory mechanism to prevent
378 over-secretion of these peptides (Pires da Silva et al., 2016). The different phosphorylation events in NOS1
379 between the NIL and SON identified in this study and the implications regarding the differential activities
380 of this enzyme in discrete cellular structures, can contribute to fully understand the role of NOS1 in MCNs
381 and other neuronal systems.

382 We have also identified a number of proteins in the SON without the presence of their corresponding
383 transcripts, and validated proteins known to be found in afferents. The SON expresses the HCRT receptors
384 *Hcrtr1* and *Hcrtr2*, the NPY receptors *Npy1r*, *Npy2r* and *Npy5r*, and the AGRP receptors *Mc3r* and *Mc4r*,
385 the later even increases in response to WD, (Pauža et al., 2021) in agreement with regulation by these
386 neuropeptides. The increase in HCRT in WD supports a role for this neuropeptide circuit in the control on
387 MCN functions. Interestingly, HCRT regulates the sleep-wake cycle (Sagi et al., 2021). It has been
388 demonstrated that WD reduces motor activity and increases slow-wave sleep (Martelli et al., 2012), so
389 HCRT could potentially be mediating these effects.

390 In order to better understand the biological functions of neurones, a comprehensive multiomic
391 understanding of activity-dependent neuronal cellular pathways and processes in distinct cellular and sub-
392 cellular compartments is needed. But in mammals, this is easier said than done. We have taken advantage
393 of the unique anatomical organisation of the HNS to document transcriptome, proteome and

394 phosphoproteome dynamics in this structure in response to neuronal activation (see graphical abstract).
395 These data show how different compartments of the HNS respond to stimulation. This multiomic
396 approach provides a wealth of new knowledge about how neuronal stimulation reshapes the proteome
397 and phosphoproteome to be utilised by the neuroscience community and beyond.

398

399 **Materials and Methods**

400 *Animals*

401 All experimental procedures involving animals were performed in strict accordance with the provision of
402 the UK Animals (Scientific Procedures) Act (1986). The study was carried out under a Home Office UK
403 licence (PPL PP9294977) and all the protocols were approved by the University of Bristol Animal Welfare
404 and Ethical Review Board.

405 Twelve male Sprague-Dawley rats weighing 250–300 g were purchased from Envigo and acclimatised for
406 10 days. Rats were maintained under a 12:12 light dark cycle (lights on 8.00 am) at a constant temperature
407 of 21–22°C and a relative humidity of 40%–50% with *ad libitum* access to food and water. Rats were housed
408 in groups of 3 with environmental enrichment consisting of nesting material, cardboard tube, and a chew
409 block. Animal cages were randomly assigned to control or WD groups. For the WD group, water was
410 removed for 48 hours with *ad libitum* access remaining for controls.

411 For proteomic analyses and Western blotting, rats were killed by striking the cranium. The brain was
412 removed from the cranium and placed in an ice-cold brain matrix to separate the forebrain from the
413 hindbrain. The pituitary gland was removed from the base of the cranium and the NIL (containing the PP
414 and the intermediate lobe) dissected from the anterior pituitary. Forebrains and NIL were immediately
415 frozen in powdered dry ice and stored at –80°C. For immunohistochemistry analyses, rats were deeply
416 anaesthetised with intraperitoneal administration of sodium pentobarbitone (100 mg/kg,) and
417 transcardially perfused with 0.1M phosphate buffered saline pH 7.4 (PBS) followed by 4% (w/v)
418 paraformaldehyde (PFA) in PBS. The brain and pituitary gland were removed, post-fixed in 4% (w/v) PFA
419 overnight and cryoprotected in 30% (w/v) sucrose in PBS prior to freezing the tissues over liquid nitrogen.
420 All sample collections were performed between 9.00 am and 12.00 pm.

421 *Protein extraction for proteomic and phosphoproteomic analyses*

422 SON samples were collected bilaterally using a 1-mm micropunch (Fine Scientific Tools) from 100 μm brain
423 coronal sections in a cryostat as described (Greenwood et al., 2014). Proteins from SON and NIL samples
424 were extracted in lysis buffer containing 50 mM Tris-HCl, pH 7.6; 150 mM NaCl; 0.1% (w/v) sodium dodecyl
425 sulfate; 0.5% (w/v) sodium deoxycholate; 1% (v/v) Nonidet P-40; 1 mM EDTA) containing the protease
426 inhibitors 1mM Phenylmethylsulfonyl fluoride (Merck, P7626), Pierce Protease Inhibitor Tablets (Thermo
427 Fisher Scientific, A32963) and Pierce Phosphatase Inhibitor Mini Tablets (Thermo Fisher Scientific,
428 A32957) in three sonication cycles of 12 seconds. Samples were then incubated in ice for 30 minutes,
429 vortexing every 5 minutes, and then centrifuged at 10000 g for 20 minutes at 4°C. The supernatant was
430 transferred to a fresh tube and protein concentrations were determined by the Bradford assay.

431 *TMT Labelling, High pH reversed-phase chromatography and Phospho-peptide enrichment.*

432 Total proteome and phospho proteome analysis were performed at the Bristol Proteomics Facility,
433 University of Bristol. Aliquots of 100 μg of each sample were digested with trypsin (2.5 μg trypsin per 100 μg
434 protein; 37°C, overnight), labelled with Tandem Mass Tag (TMTpro) sixteen plex reagents according to the
435 manufacturer's protocol (Thermo Fisher Scientific, Loughborough, LE11 5RG, UK) and the labelled samples
436 pooled.

437 For the total proteome analysis, an aliquot of 50 μg of the pooled sample was desalted using a SepPak
438 cartridge according to the manufacturer's instructions (Waters, Milford, Massachusetts, USA). Eluate from
439 the SepPak cartridge was evaporated to dryness and resuspended in buffer A (20 mM ammonium
440 hydroxide, pH 10) prior to fractionation by high pH reversed-phase chromatography using an Ultimate
441 3000 liquid chromatography system (Thermo Fisher Scientific). In brief, the sample was loaded onto an
442 XBridge BEH C18 Column (130Å, 3.5 μm , 2.1 mm X 150 mm, Waters, UK) in buffer A and peptides eluted
443 with an increasing gradient of buffer B (20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95%
444 (w/v) over 60 minutes. The resulting fractions (20 in total) were evaporated to dryness and resuspended
445 in 1% (v/v) formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Lumos mass
446 spectrometer (Thermo Scientific).

447 For the Phospho proteome analysis, the remainder of the TMT-labelled pooled sample was desalted using
448 a SepPak cartridge (Waters, Milford, Massachusetts, USA). The eluate from the SepPak cartridge was
449 evaporated to dryness and subjected to TiO₂-based phosphopeptide enrichment according to the
450 manufacturer's instructions (Pierce). The flow-through and washes from the TiO₂-based enrichment were
451 then subjected to FeNTA-based phosphopeptide enrichment according to the manufacturer's instructions

452 (Pierce). The phospho-enriched samples were again evaporated to dryness and then resuspended in 1%
453 formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Lumos mass spectrometer
454 (Thermo Scientific).

455 *Nano-LC Mass Spectrometry*

456 High pH RP fractions (Total proteome analysis) or the phospho-enriched fractions (Phospho-proteome
457 analysis) were further fractionated using an Ultimate 3000 nano-LC system in line with an Orbitrap Fusion
458 Lumos mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid were injected onto
459 an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After washing with 0.5% (v/v) acetonitrile
460 0.1% (v/v) formic acid peptides were resolved on a 250 mm × 75 µm Acclaim PepMap C18 reverse phase
461 analytical column (Thermo Scientific) over a 150 min organic gradient, using 7 gradient segments (1-6%
462 solvent B over 1min., 6-15% B over 58min., 15-32%B over 58min., 32-40%B over 5min., 40-90%B over
463 1min., held at 90%B for 6min and then reduced to 1%B over 1min.) with a flow rate of 300 nl min⁻¹. Solvent
464 A was 0.1% (v/v) formic acid and Solvent B was aqueous 80% (v/v) acetonitrile in 0.1% (v/v) formic acid.
465 Peptides were ionized by nano-electrospray ionization at 2.0kV using a stainless-steel emitter with an
466 internal diameter of 30 µm (Thermo Scientific) and a capillary temperature of 300°C.

467 All spectra were acquired using an Orbitrap Fusion Lumos mass spectrometer controlled by Xcalibur 3.0
468 software (Thermo Scientific) and operated in data-dependent acquisition mode using an SPS-MS3
469 workflow. FTMS1 spectra were collected at a resolution of 120 000, with an automatic gain control (AGC)
470 target of 200 000 and a max injection time of 50ms. Precursors were filtered with an intensity threshold
471 of 5000, according to charge state (to include charge states 2-7) and with monoisotopic peak
472 determination set to Peptide. Previously interrogated precursors were excluded using a dynamic window
473 (60s +/-10ppm). The MS2 precursors were isolated with a quadrupole isolation window of 0.7m/z. ITMS2
474 spectra were collected with an AGC target of 10 000, max injection time of 70ms and CID collision energy
475 of 35%.

476 For FTMS3 analysis, the Orbitrap was operated at 50 000 resolution with an AGC target of 50 000 and a
477 max injection time of 105ms. Precursors were fragmented by high energy collision dissociation (HCD) at
478 a normalised collision energy of 60% to ensure maximal TMT reporter ion yield. Synchronous Precursor
479 Selection (SPS) was enabled to include up to 10 MS2 fragment ions in the FTMS3 scan.

480 *Data processing*

481 The raw data files were processed and quantified using Proteome Discoverer software v2.1 (Thermo
482 Scientific) and searched against the UniProt Rat database (downloaded July 2021: 35859 entries) using
483 the SEQUEST HT algorithm. Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance
484 was set at 0.6Da. Search criteria included oxidation of methionine (+15.995Da), acetylation of the protein
485 N-terminus (+42.011Da) and Methionine loss plus acetylation of the protein N-terminus (-89.03Da) as
486 variable modifications and carbamidomethylation of cysteine (+57.0214) and the addition of the TMTpro
487 mass tag (+304.207) to peptide N-termini and lysine as fixed modifications. For the Phospho-proteome
488 analysis, phosphorylation of serine, threonine and tyrosine (+79.966) was also included as a variable
489 modification. Searches were performed with full tryptic digestion and a maximum of 2 missed cleavages
490 were allowed.

491 *Protein abundance processing*

492 Protein groupings were determined by PD2.2, however, the master protein selection was improved with
493 an in-house script. This enables us to infer biological trends more effectively in the dataset without any
494 loss in the quality of identification or quantification. The MS data were searched against the human
495 Uniprot database retrieved on 2022-01-05 and updated with additional annotation information on 2022-
496 01-20.

497 The protein abundances were normalised within each sample to total peptide amount, and then scaled
498 to the abundance of the common pool sample (a single representative sample run in each separate TMT
499 experiment) to allow comparisons between experiments. The scaled abundances were then Log2
500 transformed to bring them closer to a normal distribution.

501 *Phosphopeptide abundance processing*

502 The phosphorylation status of identified peptide spectral matches (PSMs) was determined by PD2.2 and
503 the site of phosphorylation predicted by PD2.2 using the PhosphoRS module. Phosphorylation sites
504 predicted by PhosphoRS with greater than 70% confidence were taken as the likely phosphorylation site,
505 and phosphopeptides identified with identical sequences and predicted phosphorylation sites, were
506 combined to provide improved quantitation and confidence. The number of PSMs used to calculate the
507 phosphosite abundance is shown in the “Contributing PSMs” column in the excel output.

508 Where a peptide is predicted to be phosphorylated (based on its mass), but the software is unable to
509 assign the site, the site is listed as “Ambiguous”. Where multiple phosphorylation events are unable to be

510 located to specific sites within a peptide, the word “Ambiguous” is repeated the corresponding number
511 of times.

512 As peptides can often be matched to multiple proteins, the list of proteins to which each peptide matched
513 was searched against the list of master proteins in the Total Protein analysis, and if a matching protein
514 was identified, this protein was used as the master protein for that peptide.

515 The experiment was performed by combining an equal amount of each sample, following TMT labelling.
516 5% of this combined sample was used for the total proteome analysis, and 95% was taken for
517 phosphopeptide enrichment and subsequent analysis of the phosphoproteome. After phospho
518 enrichment we would not necessarily expect the samples to contain the same amount of
519 phosphopeptides, due to biological differences in the levels of phosphorylation between the conditions.
520 As such, normalisation of phosphopeptide abundance was performed using the normalisation factor
521 generated from analysis of the corresponding samples in the total protein dataset. The samples were then
522 scaled to the corresponding pool in the same manner as occurred with the total proteome.

523 When total protein data is available for the phosphopeptide, the Log2 Scaled Protein abundance was
524 subtracted from the Log2 Scaled Phosphopeptide abundance to adjust the phosphopeptide abundance
525 for any changes in the total protein. As such, if a constitutively phosphorylated protein doubles in its
526 protein abundance as a result of a condition of interest, the Log2 Scaled Phosphopeptide Abundance will
527 show a doubling in the abundance of the phosphopeptide, however the Adjusted Log2 Phosphopeptide
528 Abundance will not show any significant change, as the same proportion of the protein is phosphorylated.

529 Statistical significance was then determined using Welch’s T-Tests between the conditions of interest. The
530 p-values were false discovery rate (FDR) corrected using the Benjamini-Hochberg method. Data were then
531 exported to excel for ease of use. Since it has been discussed that the use of multiple testing corrected
532 FDR may be too blunt and restrictive for proteomic analysis [18], especially when analysing such an
533 heterogeneous and complex tissue as the brain [19-24], we considered uncorrected $p < 0.05$ as
534 differentially produced proteins and phosphosites in all our SON and NIL analysis. All data have been
535 deposited at the ProteomeXchange Consortium via the PRIDE partner repository (Perez-Riverol et al.,
536 2019) with the dataset identifier PXD033401.

537 *Data analysis*

538 Principal component analysis (PCAs) were calculated using the FactoMineR package, and then plotted
539 using the ggplot2 package. Principal Components 1 and 2 were plotted against each other to give an
540 indication of the main sources of variance, and 3 and 4 were plotted to infer any further trends.

541 In volcano plots, for each comparison the $-\log_{10}$ p-value of each protein was plotted against the log₂ fold
542 change using GraphPad Prism 8.4.3. Proteins where $p < 0.05$ are highlighted in blue and red.

543 Gene Ontology (GO) gene set enrichment analysis was performed using the gProfiler2 package (Kolberg
544 et al., 2020) in R (R core team, 2021, version 4.0.3) (R Core Team, 2021) using a significance threshold of
545 < 0.05 Padj for enriched terms. A background list of all detectable proteins produced in each tissue was
546 used. Databases searched included GO:MF, GO:CC, GO:BP and KEGG. Ontologies for the synapse was
547 performed using SynGO (Koopmans *et al.*, 2019).

548 The phosphorylation state change (Δ Ps) value calculation was adapted from Wang *et al.* (2018). Briefly,
549 the Δ Ps values for protein isoforms encoded by the same gene were determined by the sum of Log₂FC of
550 all phosphorylated peptides with statistically significant changes ($p < 0.05$) in both SON and NIL when
551 comparing the WD and control groups in the phosphoproteome data. We next calculated the average
552 standard deviation (SD) of adjusted log₂ normalised abundance from all identified phosphopeptides in
553 the SON (SD = 0.17) and NIL (SD = 0.2). We applied a cut-off at ± 0.34 for the SON and ± 0.40 for the NIL (> 2
554 SD) to represent the cumulative protein phosphorylation, determining the hyperphosphorylated and
555 hypophosphorylated phosphoproteins on those tissues in response to WD.

556 We classified changes in the proteome and Δ Ps as endogenous peptides, enzymes, G protein-coupled
557 receptors (GPCRs), catalytic receptors, channels, transporters, transcription factors, and other
558 pharmacological targets using the functional classification of the International Union of Basic and Clinical
559 Pharmacology (Harding *et al.*, 2022) in association with a manually curated list of validated human
560 transcription factors (Lambert *et al.*, 2018). Only the proteins with an existing entry in these databases
561 were catalogued according to this classification. The same approach was used to characterise the newly
562 discovered peptides without, or very low mRNA expressed in the SON.

563 Mapping of phosphosites and changes in phosphorylation to the protein sequence was done by using
564 PhosphoSitePlus (<https://www.phosphosite.org>).

565 The relationship between basal and stimulated transcriptomes and proteomes was examined by
566 comparing the proteome output obtained in the present study in basal conditions and after 48 h WD with

567 previous SON transcriptomic analysis in Wistar Han rats in basal conditions and following 72 h WD (Pauža
568 et al., 2021). It is important to note that SONs were collected by the same researcher minimising variability
569 during sample collection and processing. To rule out the impact of strain, we compared Wistar Han rats
570 (Pauža et al., 2021) and Sprague-Dawley rats RNAseq datasets (unpublished) and found that SON
571 transcriptomes from both rat strains were highly correlated (Spearman $r = 0.940$, p -value < 0.0001).

572 *Immunohistochemistry*

573 Coronal sections of the forebrain containing the hypothalamus and NILs were cut on a cryostat at 40 μ m
574 and kept in PBS at 4°C. To prevent nonspecific protein binding, sections were blocked in PBS containing
575 0.3% (v/v) Triton X-100, 4% (w/v) bovine serum albumin (BSA), and 5% (v/v) donkey serum at RT for 1
576 hour. Following this, the NIL sections were incubated overnight at 4°C with the primary antibodies against
577 NOS1 (1:200, Santa Cruz biotechnology, sc-5302), phospho-nNOS (Ser852) (1:100, Thermo Fisher
578 Scientific, PA5-38305), phospho-Synapsin I (Ser62, Ser67) (1:200, Millipore, AB9848), phospho-Synapsin 2
579 (Ser425) (1:200, Thermo Fisher Scientific, PA5-64855), and Synapsin (1:200, Cell Signaling Technology,
580 2312S) in PBS containing 0.3% (v/v) Triton X-100, 4% (w/v) BSA, and 1% (v/v) donkey serum. Tissue
581 sections containing the SON were incubated with antibodies against NOS1 (1:200, Santa Cruz
582 biotechnology, sc-5302), Orexin A/Hypocretin-1 (1:1000, R and D Systems, MAB763) Phospho-JUND
583 (Ser255) (1:100, Thermo Fisher Scientific, PA5-104821), Phospho-nNOS (Ser1417) (1:500, Thermo Fisher
584 Scientific, PA1-032), Phospho-Stathmin 1 (Ser24) (1:200, MyBioSource, MBS9600965), Phospho-S6
585 Ribosomal Protein (Ser240/244) (1:500, Cell Signaling Technology, 5364S), Stathmin 1 (1:500, GeneTex,
586 GTX104707) and S6 Ribosomal Protein (1:100, Cell Signaling Technology 2317S) in PBS containing 0.3%
587 (v/v) Triton X-100, 4% (w/v) BSA, and 1% (v/v) donkey serum. All antibodies were incubated at 4°C
588 overnight, with the exemption of the antibodies against Orexin A/Hypocretin-1 and Phospho-Stathmin 1
589 (Ser24) that were incubated for 48 hours. Following incubation with the primary antibodies, sections were
590 washed in PBS and incubated with the secondary antibodies donkey anti-rabbit Alexa Fluor Plus 488
591 (Thermo Fisher Scientific, A32790) and donkey anti-mouse Alexa Fluor 594 (Molecular Probes, A-21203)
592 at a 1:500 dilution in PBS containing 0.1% (v/v) Triton, 4% (w/v) BSA, and 1% (v/v) donkey serum at RT for
593 1 h. Then, the sections were washed in PBS, incubated with 4',6-Diamidino-2-phenylindole
594 dihydrochloride (DAPI, D1306; Molecular Probes) in PBS and mounted with ProLong Gold Antifade
595 Mountant (Thermo Fisher Scientific, P36930).

596 Images were acquired using a Leica SP5-II AOBS confocal laser scanning microscope attached to a Leica
597 DMI 6000 inverted epifluorescence microscope with a 20x and a 63x PL APO CS lens. Raw image files were
598 processed to generate composite images using the open access image analysis software, Fiji.

599 *Western Blot*

600 Protein extraction from the NIL was performed as described (Greenwood et al., 2015a). Protein samples
601 were prepared to 1× Laemmli buffer solution (2% w/v SDS, 10% v/v glycerol, 5% v/v 2-mercaptoethanol,
602 0.002% w/v bromophenol blue and 0.125 M Tris HCl, pH 6.8). Samples were heated at 95°C in a hot block
603 for 5 minutes. For semiquantitative analysis of protein levels, 20 µg/lane of total protein (determined in
604 duplicate by Bio-Rad Protein Assay with BSA as standards) was loaded for control and WD samples.
605 Proteins were fractionated on 8% (w/v) sodium dodecyl sulfate polyacrylamide gels and transferred to
606 Immobilon®-P PVDF Membrane (Merck, IPVH00010). Membranes were incubated in 5% (w/v) BSA in Tris-
607 buffered saline (150 mM NaCl; 20 mM Tris-HCl, pH 7.6) with 0.1% (v/v) Tween 20 (TBS-T) for 1 hour
608 followed by incubation with the primary antibodies NOS1 (1:200, Santa Cruz biotechnology, sc-5302),
609 phospho-nNOS (Ser852) (1:1000, Invitrogen, PA5-38305), phospho-Synapsin I (Ser62,Ser67) (1:1000,
610 Merk, AB9848), phospho-Synapsin 2 (Ser425) (1:5000, Invitrogen, PA5-64855), Synapsin (1:1000, Cell
611 Signaling Technology, 2312S) and Tubulin (1:5000, Covance, MMS-489P) overnight at 4°C. Following three
612 washes in TBS-T, the membranes were incubated with the appropriate secondary antibody conjugated
613 with horseradish peroxidase for 1 hour. After three washes in TBS-T, the signal was detected using
614 chemiluminescence SuperSignal West Dura Extended Duration Substrate reagent (Thermo Fisher
615 Scientific, 34075). Immunoblots were stripped in Restore Western Blot Stripping Buffer (Thermo Fisher
616 Scientific, 21059) and reprobbed to assess the multiple proteins in the same blot.

617 *Statistical analysis*

618 Statistical analyses were performed with GraphPad 8.4.3 Software. For western blot signal quantification,
619 assessment of the normality of data was performed by Shapiro-Wilk test. Means between two groups
620 were compared using independent-sample unpaired Student's t tests where data are expressed as box
621 and whisker plots. For the P-SYN1 and P-SYN quantifications, one sample was excluded from the analysis
622 due to the absence of total SYN signal (**Figure S1**), otherwise all samples were included in the analysis.
623 Spearman correlation analysis were also performed in GraphPad Prism Prism 8.4.3. In all cases $p < 0.05$
624 was considered statistically significant.

625 **Data and code availability**

626 All data are available in the manuscript or supplemental information. The LC-MS/MS proteomics and
627 phosphoproteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-
628 Riverol *et al.*, 2019) partner repository with the dataset identifier PXD033401. Any additional information
629 is available from the lead contact upon request.

630

631 **Acknowledgments**

632 The authors gratefully acknowledge Dr Kate J. Heesom and Dr Philip A Lewis from the University of Bristol
633 Proteomics Facility for their support and assistance. We also thank the Wolfson Bioimaging Facility. This
634 research was supported by grants from the Biotechnology and Biological Sciences Research Council
635 (BBSRC; BB/R016879/1) to D.M., S.B.L. and M.P.G. and from the Leverhulme Trust (RPG-2017-287) to D.M.
636 and M.P.G. Students were supported by grants from the Biotechnology and Biological Sciences Research
637 Council-SWBio DTP programme (BBSRC BB/M009122/1) to B.T.G., and the British Heart Foundation to
638 A.G.P (BHF FS/17/60/33474) and to N.B. (FS/4yPhD/F/21/34162).

639

640 **Competing interests:**

641 The authors declare that they have no conflicts of interest.

642

643 **Figure legends**


644

645

646

647

648




650 **Figure 1 Quantitative proteome and phosphoproteome of the rat supraoptic nucleus (SON).**

- 651 (A) Graphical representation of the experimental approach. (1) 12 adult Sprague-Dawley rats were
652 divided into 2 groups: 6 control with constant access to water and 6 subjected to a 48-hour water
653 deprivation protocol (WD) to activate magnocellular neurones (MCNs). (2) The supraoptic nucleus
654 (SON, mainly containing MCN cell bodies and dendrites) was punched from the hypothalamus and
655 the neurointermediate lobe (NIL, mainly containing axonal terminals from the posterior pituitary as
656 well as the intermediate lobe) was dissected from the anterior pituitary. (3) Proteins from SON and
657 NIL were extracted and processed for Nano-LC Mass Spectrometry (LC-MS/MS). (4) Proteomics and
658 phosphoproteomic determinations were performed by LC-MS/MS. Generated using BioRender
659 (<https://biorender.com/>).
- 660 (B) Principal component analysis (PCA) of the SON proteome and phosphoproteome in control (blue, n
661 = 6) and WD rats (red; n = 6).
- 662 (C) Volcano plot of WD vs control SON proteome showing 247 upregulated (p-value <0.05, red) and 78
663 downregulated (p-value <0.05, blue) proteins.
- 664 (D) Volcano plot of WD vs control SON phosphoproteome showing 252 hyperphosphorylation (p-value
665 <0.05, red) and 36 hypophosphorylation (p-value <0.05, blue) events.
- 666 (E) Venn diagram showing 23 proteins in common with changes at the proteome and
667 phosphoproteome level in response to WD.
- 668 (F) Phospho raw abundance for S244-p S6, S1412-p NOS1, S25-p STMN1 and S255-p JUND in the SON
669 according to LC-MS/MS between control (n = 6) and WD (n = 6) rats.
- 670 (G) Immunohistochemistry against S244-p S6 in the SON of control and (G') WD rats.
- 671 (H) Immunohistochemistry against S6 in the SON of control and (H') WD rats.
- 672 (I) Immunohistochemistry against S1412-p NOS1 in the SON of control and (I') WD rats.
- 673 (J) Immunohistochemistry against NOS1 in the SON of control and (J') WD rats.
- 674 (K) Immunohistochemistry against S25-p STMN1 in the SON of control and (K') WD rats.
- 675 (L) Immunohistochemistry against STMN1 in the SON of control and (L') WD rats.
- 676 (M) Immunohistochemistry against S255-p JUND in the SON of control and (M') WD rats. Images are
677 representative of n = 4. Scale bar represents 25 μ m.

678

679



681 **Figure 2 Quantitative proteome and phosphoproteome of the rat neurointermediate lobe (NIL)**

682 (A) Principal component analysis (PCA) of the NIL proteome and phosphoproteome in control (blue, n =
683 6) and water-deprived (WD) rats (red; n = 6).

684 (B) Volcano plot of WD vs control NIL proteome showing 276 upregulated (p-value <0.05, red) and 573
685 downregulated (p-value <0.05, blue) proteins.

686 (C) Volcano plot of WD vs control NIL phosphoproteome showing 746 hyperphosphorylation (p-value
687 <0.05, red) and 755 hypophosphorylation (p-value <0.05, blue) events.

688 (D) Venn diagram showing 151 proteins in common with changes at the proteome and
689 phosphoproteome level in response to WD

690 (E) Phospho raw abundance for S67-p SYN1, S426-p SYN2 and S426-p SYN2 in the NIL according to LC-
691 MS/MS between control (n = 6) and WD (n = 6) rats. Western blotting analysis of S67-p SYN1
692 (normalised against SYN1), S426-p SYN2 (normalised against SYN2) and S847-p NOS1 (normalised
693 against NOS1) in control (n = 5) and WD NILs (n = 5 for S847-p NOS1 and n = 4 for S67-p SYN1 and
694 S426-p SYN2).

695 (F) Immunohistochemistry against S67-p SYN1 and arginine vasopressin (AVP), S426-p SYN2 and AVP
696 and S847-p NOS1 and NOS1 in the pituitary gland of control rats showing the anterior pituitary (AP),
697 intermediate lobe (IL) and posterior pituitary (PP). Images are representative of n = 4. Scale bar
698 represents 75 μ m.

699 (G) Immunohistochemistry against S67-p SYN1, S426-p SYN2 and S847-p NOS1 in the PP of control and
700 WD rats. Images are representative of n = 4. Scale bar represents 25 μ m.

701

702





703

704

705

706

707



709 **Figure 3 Pathway analyses and functional classification of the proteomes of supraoptic nucleus (SON)**
710 **and neurointermediate lobe (NIL)**

711 (A) Pathway analysis of changes in the SON proteome as a result of water deprivation (WD) using
712 GO and KEGG databases. Dot plot of all enriched terms retrieved for each category ranked
713 according to P_{Adj} value from top to bottom in increasing order. The top 10 most significant
714 associated differentially expressed proteins of each over-represented category are shown as
715 dots coloured based on Log2FC and sized according to total normalised protein expression
716 following WD.

717 (B) Pathway analysis of changes in the NIL proteome as a result of WD using GO and KEGG
718 databases. Dot plot of up to 15 enriched terms retrieved for each category ranked according to
719 P_{Adj} value from top to bottom in increasing order. The top 10 most significant associated
720 differentially expressed proteins of each over-represented category are shown as dots coloured
721 based on Log2FC and sized according to total normalised protein expression following WD.

722 (C) Proteome Log2FC changes in the rat SON as a consequence of WD categorised according to their
723 pharmacological classification or their function as a transcription factor.

724 (D) Proteome Log2FC changes in the rat NIL as a consequence of WD categorised according to their
725 pharmacological classification or their function as a transcription factor.

726

727

728

729

730


731

732

733

734

735



738 **Figure 4 Pathway analyses and functional classification of the phosphoproteomes of supraoptic**
739 **nucleus (SON) and neurointermediate lobe (NIL)**

740 (A) Pathway analysis of changes in the SON phosphoproteome as a result of water deprivation (WD)
741 using GO and KEGG databases. Dot plot of all enriched terms retrieved for each category ranked
742 according to P_{Adj} value from top to bottom in increasing order. The top 20 proteins with most
743 significant phosphorylation changes in a phosphosite are shown as a dot indicating the total
744 number of phosphorylation events in that protein following WD.

745 (B) Pathway analysis of changes in the NIL phosphoproteome as a result of WD using GO and KEGG
746 databases. Dot plot of up to 15 enriched terms retrieved for each category ranked according to
747 P_{Adj} value from top to bottom in increasing order. The top 15 proteins with most significant
748 phosphorylation changes in a phosphosite are shown as a dot indicating the total number of
749 phosphorylation events in that protein following WD.

750 (C) Global overall phosphorylation state change (ΔPs) analysis of phosphoproteins between control
751 and WD rats in the SON. Numbers of hyperphosphorylated (Hyper) and hypophosphorylated
752 (Hypo) peptides are shown. Dotted lines, $\Delta Ps = \pm 0.34$.

753 (D) Global ΔPs analysis of phosphoproteins between control and WD rats in the NIL. Numbers of
754 hyperphosphorylated (Hyper) and hypophosphorylated (Hypo) peptides are shown. Dotted
755 lines, $\Delta Ps = \pm 0.4$.

756 (E) ΔPs changes in the rat SON as a consequence of WD categorised according to their
757 pharmacological classification or their function as a transcription factor.

758 (F) ΔPs changes in the rat NIL as a consequence of WD categorised according to their
759 pharmacological classification or their function as a transcription factor.

760

761

762


763

764

765



766

Microtubule cytoskeleton organisation



767
 768 **Figure 5 Phosphorylation events regulating cytoskeletal remodelling in the stimulated supraoptic**
 769 **nucleus**

770 Mapping the phosphosites and hyperphosphorylation and hypophosphorylation events in response to water
 771 deprivation (WD) in proteins involved in microtubule cytoskeleton organisation. Protein
 772 domains include CA: Spectrin-binding region of Ca²⁺-Calmodulin, CAMS: CAMSAP Calponin-
 773 homology domain, CAMSAP: Calmodulin-regulated spectrin-associated CCK domain, DUF4:
 774 DUF4482 Domain of unknown function, KA1: Kinase associated domain 1, L27: L27 domain, MP:
 775 Unstructured region 10 on multiple PDZ protein, PDZ: post synaptic density protein (PSD95)
 776 domain, PH: Pleckstrin homology domain, PKinase: Protein kinase domain, SLD: Stathmin-like
 777 domain, SR: serine-arginine-rich region, T: Tau and MAP protein tubulin-binding repeat, TOG1,2:
 778 tumour overexpressed gene domains, UBA: ubiquitin-associated domain.



● Hyperphosp. ● Phosphosite ● Hypophosp. * Novel phosphosite.

780 **Figure 6 Phosphorylation events regulating synaptic processes in the stimulated neurointermediate**
781 **lobe (NIL)**

- 782 (A) SynGO cellular compartment (cc) enrichment analysis of all the proteins undergoing
783 phosphorylation events in response to water deprivation (WD) in the NIL.
- 784 (B) SynGO biological processes (bp) enrichment analysis of all the proteins undergoing
785 phosphorylation events in response to WD in the NIL.
- 786 (C) Mapping the phosphosites and hyper and hypophosphorylation events in response to WD in
787 proteins involved in the synaptic vesicle cycle including the regulation of the synaptic vesicle
788 cycle, synaptic vesicle clustering and synaptic vesicle exocytosis and in proteins involved in
789 presynaptic dense core vesicle exocytosis. Protein domains include Abl HHR: Abl-interactor
790 homeo-domain homologous region, C1: phorbol esters/diacylglycerol binding domain C1
791 domain, C2: Ca²⁺-dependent C2 domain, DBD: dynactin 1 binding domain, DCV: dense core
792 vesicle association domain, FYVE: FYVE zinc finger domain, GED: Dynamin GTPase effector
793 domain, GTPase: GTPase domain, JMD: juxta-membrane domain, MHD1,2: Munc13-homology
794 domains, P-rich NT: proline-rich N-terminal domain, PDZ: post synaptic density domain, PH:
795 Pleckstrin homology domain, Rho GDI: RHO protein GDP dissociation inhibitor, Syn A, B, C, D, E,
796 F, G, H, J: Synapsin domain A, B, C, D, E, F, G, H, J, TMD: transmembrane domain, WD: WD40
797 repeat or beta-transducin repeat, Z: Piccolo Zn-finger.

798

799

800


801

802

803

804

805



807 **Figure 7 Multi-omic integration of stimulated supraoptic nucleus (SON) and neurointermediate lobe**
808 **(NIL)**

- 809 (A) Spearman correlation analysis of Log₂FC changes in the rat SON proteome and Log₂FC changes
810 in the SON transcriptome in response to water deprivation (WD).
- 811 (B) Spearman correlation analysis of Log₂FC changes in the rat NIL proteome and Log₂FC changes in
812 the SON transcriptome in response WD.
- 813 (C) Spearman correlation analysis of Log₂FC changes in the rat NIL proteome and SON proteome in
814 response to WD.
- 815 (D) Spearman correlation analysis of Δ Ps changes in the rat NIL and SON in response to WD.
- 816 (E) Spearman correlation analysis of Δ Ps changes in the rat NIL and Log₂FC changes in the SON
817 proteome in response to WD.
- 818 (F) Spearman correlation analysis of Log₂FC changes in the rat NIL proteome and Δ Ps changes in
819 the NIL in response to WD.
- 820 (G) Mapping the phosphosites and hyperphosphorylation events in response to WD in Vasopressin-
821 neurophysin 2-copeptin (AVP), Oxytocin-neurophysin 1 (OXT), Proenkephalin-B (PDYN),
822 Peptidylglycine alpha-amidating monooxygenase (PAM) in the SON and NIL.

823

824

825

826

827

828

829

830



831

832

833

834

835



836

837

838

839


840 **Figure 8 Basal state transcriptome vs proteome integration**

841 (A) Venn diagram showing the number of overlapping proteins in the SON and NIL and genes in the
842 SON in control conditions.

843 (B) Schematic representation of the gene and protein dynamics in the SON and NIL in control
844 conditions according to comparisons from the Venn diagram. Generated using BioRender
845 (<https://biorender.com/>).

846 (C) Proteins detected in the SON without or very low transcripts in this structure categorised
847 according to their pharmacological classification or their function as a transcription factor.

848 (H) Immunohistochemistry against HCRT, NPY and AGRP in the SON of control and water-deprived (WD)
849 rats. Images are representative of n = 4. Scale bar represents 25 μm .



850

851 Graphical abstract

852

853

854

855

856


857

858

859

860

861



863 Supplementary Figure 1. Complete Western Blots with control and 48 hours water deprived (WD) blotted
864 against P-Syn1 (A), P-Syn2 (B), Syn (C), P-Nos (D) and Nos (E).

865 (C) Due to the lack of Syn signal in the last lane (*), this sample was excluded from the P-Syn1 and P-Syn2
866 analysis.

867 (D) This membrane was covered during signal detection to prevent signal bleed-through from previous
868 rounds of protein detection.

869 (F) Normalising the signal to tubulin rendered the same results as normalising to total Syn and total Nos.

870

871

872

873

874

875

876

877

878

879

880

881

882


883

884

885


A

NOS1 in SON



B

NOS1 in NIL



● Hyperphosp. ● Phosphosite ● Hypophosp. * Novel phosphosite.

886

887 Supplementary Figure 2. Mapping the phosphosites and hyper and hypophosphorylation events in NOS1

888 in response to water deprivation in the (A) SON and (B) NIL.

889

890

891

892

893

894

895

896

897

898

899 References

- 900 Barad, Z., Jacob-Tomas, S., Sobrero, A., Lean, G., Hicks, A.I., Yang, J., Choe, K.Y., and Prager-Khoutorsky,
901 M. (2020). Unique Organization of Actin Cytoskeleton in Magnocellular Vasopressin Neurons in Normal
902 Conditions and in Response to Salt-Loading. *eNeuro* 7. 10.1523/ENEURO.0351-19.2020.
- 903 Báñez-López, S., Konopacka, A., Cross, S.J., Greenwood, M., Skarveli, M., Murphy, D., and Greenwood,
904 M.P. (2022). Transcriptional and post-transcriptional regulation of oxytocin and vasopressin gene
905 expression by CREB3L1 and CAPRIN2. *Neuroendocrinology*. 10.1159/000522088.
- 906 Berwin, B., Floor, E., and Martin, T.F. (1998). CAPS (mammalian UNC-31) protein localizes to membranes
907 involved in dense-core vesicle exocytosis. *Neuron* 21, 137-145. 10.1016/s0896-6273(00)80521-8.
- 908 Bishop, L., Dimaline, R., Blackmore, C., Deavall, D., Dockray, G.J., and Varro, A. (1998). Modulation of the
909 cleavage of the gastrin precursor by prohormone phosphorylation. *Gastroenterology* 115, 1154-1162.
910 10.1016/s0016-5085(98)70086-1.
- 911 Brown, C.H. (2016). Magnocellular Neurons and Posterior Pituitary Function. *Compr Physiol* 6, 1701-
912 1741. 10.1002/cphy.c150053.
- 913 Brownstein, M.J., Russell, J.T., and Gainer, H. (1980). Synthesis, transport, and release of posterior
914 pituitary hormones. *Science* 207, 373-378. 10.1126/science.6153132.
- 915 Burbach, J.P., Luckman, S.M., Murphy, D., and Gainer, H. (2001). Gene regulation in the magnocellular
916 hypothalamo-neurohypophysial system. *Physiol Rev* 81, 1197-1267. 10.1152/physrev.2001.81.3.1197.
- 917 Chen, X., Xiang, X., Xie, T., Chen, Z., Mou, Y., Gao, Z., Xie, X., Song, M., Huang, H., Gao, Z., and Chen, M.
918 (2021). Memantine protects blood-brain barrier integrity and attenuates neurological deficits through
919 inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement
920 of peroxynitrite-related matrix metalloproteinase-9/NLRP3 inflammasome activation. *Neuroreport* 32,
921 228-237. 10.1097/WNR.0000000000001577.
- 922 Chi, P., Greengard, P., and Ryan, T.A. (2003). Synaptic vesicle mobilization is regulated by distinct
923 synapsin I phosphorylation pathways at different frequencies. *Neuron* 38, 69-78. 10.1016/s0896-
924 6273(03)00151-x.
- 925 Chronwall, B.M., DiMaggio, D.A., Massari, V.J., Pickel, V.M., Ruggiero, D.A., and O'Donohue, T.L. (1985).
926 The anatomy of neuropeptide-Y-containing neurons in rat brain. *Neuroscience* 15, 1159-1181.
927 10.1016/0306-4522(85)90260-x.
- 928 Costa, C.J., and Willis, D.E. (2018). To the end of the line: Axonal mRNA transport and local translation in
929 health and neurodegenerative disease. *Dev Neurobiol* 78, 209-220. 10.1002/dneu.22555.
- 930 da Silva, M.P., Ventura, R.R., and Varanda, W.A. (2013). Hypertonicity increases NO production to
931 modulate the firing rate of magnocellular neurons of the supraoptic nucleus of rats. *Neuroscience* 250,
932 70-79. 10.1016/j.neuroscience.2013.06.067.
- 933 Dapic, I., Uwugiaren, N., Jansen, P.J., and Corthals, G.L. (2017). Fast and Simple Protocols for Mass
934 Spectrometry-Based Proteomics of Small Fresh Frozen Uterine Tissue Sections. *Anal Chem* 89, 10769-
935 10775. 10.1021/acs.analchem.7b01937.
- 936 Date, Y., Ueta, Y., Yamashita, H., Yamaguchi, H., Matsukura, S., Kangawa, K., Sakurai, T., Yanagisawa, M.,
937 and Nakazato, M. (1999). Orexins, orexigenic hypothalamic peptides, interact with autonomic,
938 neuroendocrine and neuroregulatory systems. *Proc Natl Acad Sci U S A* 96, 748-753.
939 10.1073/pnas.96.2.748.
- 940 Dutra, S.G.V., Paterson, A., Monteiro, L.R.N., Greenwood, M.P., Greenwood, M.P., Amaral, L.S., Melo,
941 M.R., Colombari, D.S.A., Colombari, E., Reis, L.C., et al. (2021). Physiological and Transcriptomic Changes
942 in the Hypothalamic-Neurohypophysial System after 24 h of Furosemide-Induced Sodium Depletion.
943 *Neuroendocrinology* 111, 70-86. 10.1159/000505997.

944 Gao, J., Hirata, M., Mizokami, A., Zhao, J., Takahashi, I., Takeuchi, H., and Hirata, M. (2016). Differential
945 role of SNAP-25 phosphorylation by protein kinases A and C in the regulation of SNARE complex
946 formation and exocytosis in PC12 cells. *Cell Signal* 28, 425-437. 10.1016/j.cellsig.2015.12.014.
947 Greenwood, M., Bordieri, L., Greenwood, M.P., Rosso Melo, M., Colombari, D.S., Colombari, E., Paton,
948 J.F., and Murphy, D. (2014). Transcription factor CREB3L1 regulates vasopressin gene expression in the
949 rat hypothalamus. *J Neurosci* 34, 3810-3820. 10.1523/JNEUROSCI.4343-13.2014.
950 Greenwood, M.P., Greenwood, M., Paton, J.F., and Murphy, D. (2015a). Control of Polyamine
951 Biosynthesis by Antizyme Inhibitor 1 Is Important for Transcriptional Regulation of Arginine Vasopressin
952 in the Male Rat Hypothalamus. *Endocrinology* 156, 2905-2917. 10.1210/en.2015-1074.
953 Greenwood, M.P., Mecawi, A.S., Hoe, S.Z., Mustafa, M.R., Johnson, K.R., Al-Mahmoud, G.A., Elias, L.L.,
954 Paton, J.F., Antunes-Rodrigues, J., Gainer, H., et al. (2015b). A comparison of physiological and
955 transcriptome responses to water deprivation and salt loading in the rat supraoptic nucleus. *Am J*
956 *Physiol Regul Integr Comp Physiol* 308, R559-568. 10.1152/ajpregu.00444.2014.
957 Harding, S.D., Armstrong, J.F., Faccenda, E., Southan, C., Alexander, S.P.H., Davenport, A.P., Pawson, A.J.,
958 Spedding, M., Davies, J.A., and Nc, I. (2022). The IUPHAR/BPS guide to PHARMACOLOGY in 2022:
959 curating pharmacology for COVID-19, malaria and antibacterials. *Nucleic Acids Res* 50, D1282-D1294.
960 10.1093/nar/gkab1010.
961 Hatton, G.I. (1997). Function-related plasticity in hypothalamus. *Annu Rev Neurosci* 20, 375-397.
962 10.1146/annurev.neuro.20.1.375.
963 Hayashi, Y., Nishio, M., Naito, Y., Yokokura, H., Nimura, Y., Hidaka, H., and Watanabe, Y. (1999).
964 Regulation of neuronal nitric-oxide synthase by calmodulin kinases. *J Biol Chem* 274, 20597-20602.
965 10.1074/jbc.274.29.20597.
966 Hicks, A.I., Barad, Z., Sobrero, A., Lean, G., Jacob-Tomas, S., Yang, J., Choe, K.Y., and Prager-Khoutorsky,
967 M. (2020). Effects of salt loading on the organisation of microtubules in rat magnocellular vasopressin
968 neurones. *J Neuroendocrinol* 32, e12817. 10.1111/jne.12817.
969 Hindmarch, C., Yao, S., Beighton, G., Paton, J., and Murphy, D. (2006). A comprehensive description of
970 the transcriptome of the hypothalamoneurohypophyseal system in euhydrated and dehydrated rats.
971 *Proc Natl Acad Sci U S A* 103, 1609-1614. 10.1073/pnas.0507450103.
972 Honnappa, S., Jahnke, W., Seelig, J., and Steinmetz, M.O. (2006). Control of intrinsically disordered
973 stathmin by multisite phosphorylation. *J Biol Chem* 281, 16078-16083. 10.1074/jbc.M513524200.
974 Johnson, K.R., Hindmarch, C.C., Salinas, Y.D., Shi, Y., Greenwood, M., Hoe, S.Z., Murphy, D., and Gainer,
975 H. (2015). A RNA-Seq Analysis of the Rat Supraoptic Nucleus Transcriptome: Effects of Salt Loading on
976 Gene Expression. *PLoS One* 10, e0124523. 10.1371/journal.pone.0124523.
977 Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E.S., and Williams, K.W. (2022). Glucagon-
978 like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. *Br J*
979 *Pharmacol* 179, 600-624. 10.1111/bph.15682.
980 Kask, A., Harro, J., von Horsten, S., Redrobe, J.P., Dumont, Y., and Quirion, R. (2002). The neurocircuitry
981 and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. *Neurosci Biobehav Rev* 26,
982 259-283. 10.1016/s0149-7634(01)00066-5.
983 Khan, M., Dhammu, T.S., Matsuda, F., Singh, A.K., and Singh, I. (2015). Blocking a vicious cycle
984 nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy. *BMC Neurosci* 16, 42.
985 10.1186/s12868-015-0179-x.
986 Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J., and Peterson, H. (2020). gprofiler2 -- an R package for gene
987 list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res* 9.
988 10.12688/f1000research.24956.2.
989 Komeima, K., Hayashi, Y., Naito, Y., and Watanabe, Y. (2000). Inhibition of neuronal nitric-oxide synthase
990 by calcium/ calmodulin-dependent protein kinase IIalpha through Ser847 phosphorylation in NG108-15
991 neuronal cells. *J Biol Chem* 275, 28139-28143. 10.1074/jbc.M003198200.

992 Konopacka, A., Greenwood, M., Loh, S.Y., Paton, J., and Murphy, D. (2015). RNA binding protein Caprin-2
993 is a pivotal regulator of the central osmotic defense response. *Elife* 4. 10.7554/eLife.09656.
994 Koopmans, F., van Nierop, P., Andres-Alonso, M., Byrnes, A., Cijssouw, T., Coba, M.P., Cornelisse, L.N.,
995 Farrell, R.J., Goldschmidt, H.L., Howrigan, D.P., et al. (2019). SynGO: An Evidence-Based, Expert-Curated
996 Knowledge Base for the Synapse. *Neuron* 103, 217-234 e214. 10.1016/j.neuron.2019.05.002.
997 Lambert, S.A., Jolma, A., Campitelli, L.F., Das, P.K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T.R.,
998 and Weirauch, M.T. (2018). The Human Transcription Factors. *Cell* 172, 650-665.
999 10.1016/j.cell.2018.01.029.
1000 Leng, G., and Ludwig, M. (2008). Neurotransmitters and peptides: whispered secrets and public
1001 announcements. *J Physiol* 586, 5625-5632. 10.1113/jphysiol.2008.159103.
1002 Martelli, D., Luppi, M., Cerri, M., Tupone, D., Perez, E., Zamboni, G., and Amici, R. (2012). Waking and
1003 sleeping following water deprivation in the rat. *PLoS One* 7, e46116. 10.1371/journal.pone.0046116.
1004 Mecawi, A.S., Ruginsk, S.G., Elias, L.L., Varanda, W.A., and Antunes-Rodrigues, J. (2015). Neuroendocrine
1005 Regulation of Hydromineral Homeostasis. *Compr Physiol* 5, 1465-1516. 10.1002/cphy.c140031.
1006 Miyata, S. (2017). Advances in Understanding of Structural Reorganization in the Hypothalamic
1007 Neurosecretory System. *Front Endocrinol (Lausanne)* 8, 275. 10.3389/fendo.2017.00275.
1008 Nagy, G., Reim, K., Matti, U., Brose, N., Binz, T., Rettig, J., Neher, E., and Sorensen, J.B. (2004). Regulation
1009 of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. *Neuron* 41,
1010 417-429. 10.1016/s0896-6273(04)00038-8.
1011 Ng, D.C., Zhao, T.T., Yeap, Y.Y., Ngoei, K.R., and Bogoyevitch, M.A. (2010). c-Jun N-terminal kinase
1012 phosphorylation of stathmin confers protection against cellular stress. *J Biol Chem* 285, 29001-29013.
1013 10.1074/jbc.M110.128454.
1014 Ni, M., and Lee, A.S. (2007). ER chaperones in mammalian development and human diseases. *FEBS Lett*
1015 *581*, 3641-3651. 10.1016/j.febslet.2007.04.045.
1016 Nordmann, J.J. (1977). Ultrastructural morphometry of the rat neurohypophysis. *J Anat* 123, 213-218.
1017 Pauža, A.G., Mecawi, A.S., Paterson, A., Hindmarch, C.C.T., Greenwood, M., Murphy, D., and
1018 Greenwood, M.P. (2021). Osmoregulation of the transcriptome of the hypothalamic supraoptic nucleus:
1019 A resource for the community. *J Neuroendocrinol* 33, e13007. 10.1111/jne.13007.
1020 Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D.J., Inuganti, A.,
1021 Griss, J., Mayer, G., Eisenacher, M., et al. (2019). The PRIDE database and related tools and resources in
1022 2019: improving support for quantification data. *Nucleic Acids Res* 47, D442-D450.
1023 10.1093/nar/gky1106.
1024 Pires da Silva, M., de Almeida Moraes, D.J., Mecawi, A.S., Rodrigues, J.A., and Varanda, W.A. (2016).
1025 Nitric Oxide Modulates HCN Channels in Magnocellular Neurons of the Supraoptic Nucleus of Rats by an
1026 S-Nitrosylation-Dependent Mechanism. *J Neurosci* 36, 11320-11330. 10.1523/JNEUROSCI.1588-16.2016.
1027 Pizzamiglio, L., Focchi, E., and Antonucci, F. (2020). ATM Protein Kinase: Old and New Implications in
1028 Neuronal Pathways and Brain Circuitry. *Cells* 9. 10.3390/cells9091969.
1029 Prager-Khoutorsky, M., Khoutorsky, A., and Bourque, C.W. (2014). Unique interweaved microtubule
1030 scaffold mediates osmosensory transduction via physical interaction with TRPV1. *Neuron* 83, 866-878.
1031 10.1016/j.neuron.2014.07.023.
1032 Qiu, J., Hindmarch, C.C., Yao, S.T., Tasker, J.G., and Murphy, D. (2011). Transcriptomic analysis of the
1033 osmotic and reproductive remodeling of the female rat supraoptic nucleus. *Endocrinology* 152, 3483-
1034 3491. 10.1210/en.2011-1044.
1035 R Core Team (2021). R: A language and environment for statistical computing. [https://www.R-](https://www.R-project.org/)
1036 [project.org/](https://www.R-project.org/).
1037 Reis, W.L., Biancardi, V.C., Son, S., Antunes-Rodrigues, J., and Stern, J.E. (2015). Carbon monoxide and
1038 nitric oxide interactions in magnocellular neurosecretory neurones during water deprivation. *J*
1039 *Neuroendocrinol* 27, 111-122. 10.1111/jne.12245.

- 1040 Sagi, D., de Lecea, L., and Appelbaum, L. (2021). Heterogeneity of Hypocretin/Orexin Neurons. *Front*
1041 *Neurol Neurosci* *45*, 61-74. 10.1159/000514964.
- 1042 Sahoo, P.K., Smith, D.S., Perrone-Bizzozero, N., and Twiss, J.L. (2018). Axonal mRNA transport and
1043 translation at a glance. *J Cell Sci* *131*. 10.1242/jcs.196808.
- 1044 Schroder, M.S., Stellmacher, A., Romorini, S., Marini, C., Montenegro-Venegas, C., Altmann, W.D.,
1045 Gundelfinger, E.D., and Fejtova, A. (2013). Regulation of presynaptic anchoring of the scaffold protein
1046 Bassoon by phosphorylation-dependent interaction with 14-3-3 adaptor proteins. *PLoS One* *8*, e58814.
1047 10.1371/journal.pone.0058814.
- 1048 Sharman, G., Ghorbel, M., Leroux, M., Beaucourt, S., Wong, L.F., and Murphy, D. (2004). Deciphering the
1049 mechanisms of homeostatic plasticity in the hypothalamo-neurohypophyseal system--genomic and gene
1050 transfer strategies. *Prog Biophys Mol Biol* *84*, 151-182. 10.1016/j.pbiomolbio.2003.11.005.
- 1051 Shi, Z., Zheng, W.C., Yang, H., Fu, X.L., Cheng, W.Y., and Yuan, W.J. (2019). Contribution of dehydration
1052 to END in acute ischemic stroke not mediated via coagulation activation. *Brain Behav* *9*, e01301.
1053 10.1002/brb3.1301.
- 1054 Tan, T.C., Valova, V.A., Malladi, C.S., Graham, M.E., Berven, L.A., Jupp, O.J., Hansra, G., McClure, S.J.,
1055 Sarcevic, B., Boadle, R.A., et al. (2003). Cdk5 is essential for synaptic vesicle endocytosis. *Nat Cell Biol* *5*,
1056 701-710. 10.1038/ncb1020.
- 1057 Tauchi, M., Zhang, R., D'Alessio, D.A., Stern, J.E., and Herman, J.P. (2008). Distribution of glucagon-like
1058 peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei. *J Chem*
1059 *Neuroanat* *36*, 144-149. 10.1016/j.jchemneu.2008.07.009.
- 1060 Theodosis, D.T., El Majdoubi, M., Pierre, K., and Poulain, D.A. (1998). Factors governing activity-
1061 dependent structural plasticity of the hypothalamoneurohypophysial system. *Cell Mol Neurobiol* *18*,
1062 285-298. 10.1023/a:1022577105819.
- 1063 Trivedi, N., Marsh, P., Goold, R.G., Wood-Kaczmar, A., and Gordon-Weeks, P.R. (2005). Glycogen
1064 synthase kinase-3beta phosphorylation of MAP1B at Ser1260 and Thr1265 is spatially restricted to
1065 growing axons. *J Cell Sci* *118*, 993-1005. 10.1242/jcs.01697.
- 1066 Wang, Z., Ma, J., Miyoshi, C., Li, Y., Sato, M., Ogawa, Y., Lou, T., Ma, C., Gao, X., Lee, C., et al. (2018).
1067 Quantitative phosphoproteomic analysis of the molecular substrates of sleep need. *Nature* *558*, 435-
1068 439. 10.1038/s41586-018-0218-8.
- 1069 Wasmeier, C., Burgos, P.V., Trudeau, T., Davidson, H.W., and Hutton, J.C. (2005). An extended tyrosine-
1070 targeting motif for endocytosis and recycling of the dense-core vesicle membrane protein phogrin.
1071 *Traffic* *6*, 474-487. 10.1111/j.1600-0854.2005.00292.x.
- 1072 Yao, S.T., Gouraud, S.S., Qiu, J., Cunningham, J.T., Paton, J.F., and Murphy, D. (2012). Selective up-
1073 regulation of JunD transcript and protein expression in vasopressinergic supraoptic nucleus neurones in
1074 water-deprived rats. *J Neuroendocrinol* *24*, 1542-1552. 10.1111/j.1365-2826.2012.02362.x.
- 1075 Yin, P., Bousquet-Moore, D., Annangudi, S.P., Southey, B.R., Mains, R.E., Eipper, B.A., and Sweedler, J.V.
1076 (2011). Probing the production of amidated peptides following genetic and dietary copper
1077 manipulations. *PLoS One* *6*, e28679. 10.1371/journal.pone.0028679.
- 1078 Zhang, B., Qiu, L., Xiao, W., Ni, H., Chen, L., Wang, F., Mai, W., Wu, J., Bao, A., Hu, H., et al. (2021).
1079 Reconstruction of the Hypothalamo-Neurohypophysial System and Functional Dissection of
1080 Magnocellular Oxytocin Neurons in the Brain. *Neuron* *109*, 331-346 e337.
1081 10.1016/j.neuron.2020.10.032.

1082